FinnCap reissued their buy rating on shares of Cello Group (LON:CLL) in a report issued on Monday. FinnCap currently has a GBX 135 ($1.82) target price on the stock.

Separately, N+1 Singer reissued a buy rating and set a GBX 131 ($1.76) price target on shares of Cello Group in a research report on Wednesday, September 20th.

Shares of Cello Group (LON:CLL) remained flat at $GBX 126 ($1.70) during midday trading on Monday. 17,881 shares of the company’s stock were exchanged, compared to its average volume of 37,703. Cello Group has a 12-month low of GBX 95.20 ($1.28) and a 12-month high of GBX 140 ($1.88).

In other news, insider Mark Bentley purchased 110,000 shares of the stock in a transaction on Wednesday, September 27th. The stock was purchased at an average price of GBX 128 ($1.72) per share, with a total value of £140,800 ($189,502.02).

ILLEGAL ACTIVITY NOTICE: “Cello Group (CLL) Given “Buy” Rating at FinnCap” was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this report on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The legal version of this report can be accessed at

About Cello Group

Cello Group plc is a United Kingdom-based healthcare and consumer strategic marketing company. The Company is engaged in providing market research, consulting and direct marketing services. The Company operates through two segments: Cello Health and Cello Signal. The Cello Health Division provides market research, consulting and communications services principally to the Company’s pharmaceutical and healthcare clients.

Receive News & Ratings for Cello Group plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cello Group plc and related companies with Analyst Ratings Network's FREE daily email newsletter.